UKASCC United Kingdom Association of Supportive Care in Cancer Trustees, Annual Report for the Period: February 1. 2025 to January 31st 2026 1. Reference and Administration Details................................. 2. Structure, Governance, and Management . 3. Objectives and Activities . 4. Achievements and Performance......................................... 5. Financial Review............................................................... 6. Plans for Future Periods
'? UKASCC 1. Reference and Administration Details Charity Name: UNITED KINGDOM ASSOCIATION FOR SUPPORTIVE CARE IN CANCER (UKASCC) Charity Registration Number: 1200940 Principal Address: 149 Dovehouse Street, London, SW3 6LB Trustees: Daniel Monnery (Chair) Elaine Tomlins (Treasurer) Richard Berman (Immediate Past President, Appointed November 2022) Ashique Ahamed (Appointed November 2022) Lesley Howells (Appointed February 2023) Benjamin Heyworth (Appointed June 2024) Jennifer Vidrine (Appointed May 2025) Anna Olsson Brown (Appointed May 2025) Matthew Carey (Appointed May 2025) Non-Trustee Board Members: Sam Ahmedzai (Patron) Charlotte Leach {Secretary) Joanne Sheppard (Workstream Lead) Shahlaa Walsh (Workstream Lead) Victoria Hedges {Workstream Lead) 2. Structure, Governance, and Management Governing Document: The charity is a charitable incorporated organisation (CIO) governed by a constitution adopted on 8 th November 2022.
UKASCC Trustee Selection: Trustees are appointed by the existing board based on a review of necessary skills and clinical experience, such as education and leadership and care of specialist groups e.g. haematology, cancer survivors and palliative care. Induction: New trustees receive an induction meeting with the Chair and treasurer to review the goals of the charity and review the statutory reporting obligations of the charity. 3. Objectives and Activities Charitable Purposes: To provide education, guidance, and support for healthcare professionals caring for people with cancer, including advocating for increased research and evidence-based practice in supportive cancer care. Public Benefit Statement: The trustees have had due regard to the Charity Commission's guidance on public benefit when planning and carrying out activities. Main Activities: The work of UKASCC is split into eight strands of activity: 1. Supporting clinical research 2. Education 3. Developing best-practice guidelines 4. Enhanced Supportive Care 5. Opioid therapy in cancer care 6. Development of a fellowship in supportive oncology 7. Mental health and emotional wellbeing in supportive care 8. Communications and marketing (including fundraising) These work streams continue to develop to provide education, support and professional development and networking to promote best practice for those receiving cancer care in the UK. During the year, we held a national webinar on oral mucositis management which was attended by 500 online attendees and we also held a successful annual conference dedicated to the breadth of
"I UKASCC supportive oncology which was attended by 235 healthcare professionals. Furthermore we have worked constructively with other organisations including the Royal College of Physicians and the Royal College of Radiologists to set the scene for more national collaborative work towards an established framework for supportive oncology: (Cancer doctors call for ur ent investment in acute and su ortive oncolo seniices to sto atient care ' ostcode lotte RCP) and (Cancer doctors call for ur ent investment in acute and su ortive oncolo services to sto atient care ostcode lotte The Ro Colle e of Radiolo ists). These documents from two important Royal Colleges call for development of standardised clinical pathways in supportive oncology, supported by an expanded and supported workforce, closer integration and the development of outcome metrics. This recognition of the core value that supportive oncology brings to cancer care is a significant milestone and we at UKASCC are excited about the opportunity to work with the colleges to progress this work. 4. Achievements and Performance Key Achievements: Our 2025 annual conference, held at Bridgewater Hall in Manchester, was our largest ever, bringing together 235 health professionals from across the UK for a three-day programme featuring global experts in their respective fields. Attendees, feedback rated all of this year's speakers either excellent or good and 60 /0 said that the content this year would change their practice. The growth of this conference event over the years has been supported by our expanding membership, which now stands at nearly 200, having increased from just 15 members in 2024. To deliver bespoke training in supportive oncology, UKASCC - in collaboration with the Royal College of Radiologists - has launched a fellowship in supportive oncology. This programme trains senior doctors in the comprehensive care of patients with cancer, from diagnosis through to post-treatment survivorship. These 12-month fellowships, supported by a UKASCC-developed curriculum, have been launched in
UKASCC four centres across the UK, with the first official Supportive Oncology Fellows due to graduate in 2026. Our advocacy for recognition and standardisation of supportive oncology as a core component of cancer care has gained significant traction, both with the aforementioned royal college declarations but also our work developing a core framework for Enhanced Supportive Care has led to its inclusion in the 2025 Getting It Right First Time (GIRFT) report for pancreatic cancer, establishing ESC as a core supportive oncology model within this cancer pathway. In recognition of our growing influence, UKASCC was formally recognised in 2025 as the UK affiliate organisation of the Multinational Association for Supportive Care in Cancer (MASCC). This international endorsement provides access to global expertise and strengthens the development of supportive oncology in the UK. We have also formed a partnership with the UK Oral Management in Cancer (UKOMIC) group and, from February 2026, UKASCC will sit on the UK SACT board following our work in toxicity management education and advocacy. 5. Financial Review Financial Position: The charity ended the year with a surplus of £13,618.32. Our principal funding sources were conference fees, income from MASCC affiliation and education grants from the pharmaceutical industry. The 2025 balance sheet is shown below:
'? UKASCC 2025 Month Income OpÈning Balance: January 2105 Conference February March Source Outgolngs Descrlptlon totals £8,291.60 EIO,396.60 900 Weblnar Honorarla E9,496.60 £12,596.60 £12,482.60 £12,382.60 £12,189.27 3100 Galen May May Ju 114 PostÈr Printing 100 Poster Printing 193.33 corrate Pens Purchase/ Promotbnal Materia August August September October November DeCefflr 2082.73 MASCC 86.4 constant rontact 330 Website Maintenance £12,102.87 Ell,772.87 75 Poster Prlze for UKASCC Conference 162.28 confence Expenses £11.697.87 £11,535.59 £13,618.32 C105ing Balance.. £13,618.32 Accounts are due to be audited by the accountant in February 2026 in line with the financial year. Reserves Policy: The trustees aim to maintain free reserves equivalent to 3-6 months of essential running costs to mitigate risks such as loss of a major grant. Going Concern: The trustees believe the charity is a going concern with sufficient funds to operate for at least the next 12 months. 6. Plans for Future Periods Future Strategy: In 2026-27, we plan to expand our events, research networks, and educational reach to include a greater number and diversity of professionals from across the UK. To that end, our aims are to: Develop our website to host educational events, including recorded webinars for members Expand our digital platform to house approved standards, guidelines, and resources
UKASCC Appoint a secretariat to support membership administration, conference organisation, and digital communications, including social media Enhance our webinar programme, including establishing an honoraria fund for expert speakers Drive forward our collaborations with other charities and the Royal Colleges to set national standards for the recognition of evidence- based supportive oncology interventions Develop a research grant programme to support innovative collaborative research in supportive oncology (supported by a grants policy and process to be developed in advance). Declaration: The truste Signe Date: 23rd January 2026 eclare that they have approved the trustees, report above. (Chair)